GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Capex-to-Revenue

Chiome Bioscience (TSE:4583) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Chiome Bioscience's Capital Expenditure for the three months ended in Dec. 2024 was 円0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was 円0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Chiome Bioscience Capex-to-Revenue Historical Data

The historical data trend for Chiome Bioscience's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Capex-to-Revenue Chart

Chiome Bioscience Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Chiome Bioscience Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chiome Bioscience's Capex-to-Revenue

For the Biotechnology subindustry, Chiome Bioscience's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Capex-to-Revenue falls into.


;
;

Chiome Bioscience Capex-to-Revenue Calculation

Chiome Bioscience's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 780.809
=0.00

Chiome Bioscience's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chiome Bioscience  (TSE:4583) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Chiome Bioscience Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiome Bioscience Business Description

Traded in Other Exchanges
N/A
Address
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience Headlines

No Headlines